PortalPublikationenProceedings from the National Cancer Institute's Second Inte...

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation

Standard

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation. / Gress, Ronald E; Miller, Jeffrey S; Battiwalla, Minoo; Bishop, Michael R; Giralt, Sergio A; Hardy, Nancy M; Kröger, Nicolaus; Wayne, Alan S; Landau, Dan A; Wu, Catherine J.

in: BIOL BLOOD MARROW TR, Jahrgang 19, Nr. 11, 01.11.2013, S. 1537-45.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Gress, RE, Miller, JS, Battiwalla, M, Bishop, MR, Giralt, SA, Hardy, NM, Kröger, N, Wayne, AS, Landau, DA & Wu, CJ 2013, 'Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation', BIOL BLOOD MARROW TR, Jg. 19, Nr. 11, S. 1537-45. https://doi.org/10.1016/j.bbmt.2013.08.010

APA

Gress, R. E., Miller, J. S., Battiwalla, M., Bishop, M. R., Giralt, S. A., Hardy, N. M., Kröger, N., Wayne, A. S., Landau, D. A., & Wu, C. J. (2013). Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation. BIOL BLOOD MARROW TR, 19(11), 1537-45. https://doi.org/10.1016/j.bbmt.2013.08.010

Vancouver

Gress RE, Miller JS, Battiwalla M, Bishop MR, Giralt SA, Hardy NM et al. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation. BIOL BLOOD MARROW TR. 2013 Nov 1;19(11):1537-45. https://doi.org/10.1016/j.bbmt.2013.08.010

Bibtex

@article{e91d855c5d3a401f901858e48132e35a,
title = "Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation",
abstract = "In the National Cancer Institute's Second Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation, the Scientific/Educational Session on the Biology of Relapse discussed recent advances in understanding some of the host-, disease-, and transplantation-related contributions to relapse, emphasizing concepts with potential therapeutic implications. Relapse after hematopoietic stem cell transplantation (HSCT) represents tumor escape, from the cytotoxic effects of the conditioning regimen and from immunologic control mediated by reconstituted lymphocyte populations. Factors influencing the biology of the therapeutic graft-versus-malignancy (GVM) effect-and relapse-include conditioning regimen effects on lymphocyte populations and homeostasis, immunologic niches, and the tumor microenvironment; reconstitution of lymphocyte populations and establishment of functional immune competence; and genetic heterogeneity within the malignancy defining potential for clonal escape. Recent developments in T cell and natural killer cell homeostasis and reconstitution are reviewed, with implications for prevention and treatment of relapse, as is the application of modern genome sequencing to defining the biologic basis of GVM, clonal escape, and relapse after HSCT.",
keywords = "Hematopoietic Stem Cell Transplantation, Humans, National Cancer Institute (U.S.), Neoplasm Recurrence, Local, Neoplasms, Transplantation Conditioning, Transplantation, Autologous, United States",
author = "Gress, {Ronald E} and Miller, {Jeffrey S} and Minoo Battiwalla and Bishop, {Michael R} and Giralt, {Sergio A} and Hardy, {Nancy M} and Nicolaus Kr{\"o}ger and Wayne, {Alan S} and Landau, {Dan A} and Wu, {Catherine J}",
note = "Published by Elsevier Inc.",
year = "2013",
month = nov,
day = "1",
doi = "10.1016/j.bbmt.2013.08.010",
language = "English",
volume = "19",
pages = "1537--45",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "11",

}

RIS

TY - JOUR

T1 - Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation

AU - Gress, Ronald E

AU - Miller, Jeffrey S

AU - Battiwalla, Minoo

AU - Bishop, Michael R

AU - Giralt, Sergio A

AU - Hardy, Nancy M

AU - Kröger, Nicolaus

AU - Wayne, Alan S

AU - Landau, Dan A

AU - Wu, Catherine J

N1 - Published by Elsevier Inc.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - In the National Cancer Institute's Second Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation, the Scientific/Educational Session on the Biology of Relapse discussed recent advances in understanding some of the host-, disease-, and transplantation-related contributions to relapse, emphasizing concepts with potential therapeutic implications. Relapse after hematopoietic stem cell transplantation (HSCT) represents tumor escape, from the cytotoxic effects of the conditioning regimen and from immunologic control mediated by reconstituted lymphocyte populations. Factors influencing the biology of the therapeutic graft-versus-malignancy (GVM) effect-and relapse-include conditioning regimen effects on lymphocyte populations and homeostasis, immunologic niches, and the tumor microenvironment; reconstitution of lymphocyte populations and establishment of functional immune competence; and genetic heterogeneity within the malignancy defining potential for clonal escape. Recent developments in T cell and natural killer cell homeostasis and reconstitution are reviewed, with implications for prevention and treatment of relapse, as is the application of modern genome sequencing to defining the biologic basis of GVM, clonal escape, and relapse after HSCT.

AB - In the National Cancer Institute's Second Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation, the Scientific/Educational Session on the Biology of Relapse discussed recent advances in understanding some of the host-, disease-, and transplantation-related contributions to relapse, emphasizing concepts with potential therapeutic implications. Relapse after hematopoietic stem cell transplantation (HSCT) represents tumor escape, from the cytotoxic effects of the conditioning regimen and from immunologic control mediated by reconstituted lymphocyte populations. Factors influencing the biology of the therapeutic graft-versus-malignancy (GVM) effect-and relapse-include conditioning regimen effects on lymphocyte populations and homeostasis, immunologic niches, and the tumor microenvironment; reconstitution of lymphocyte populations and establishment of functional immune competence; and genetic heterogeneity within the malignancy defining potential for clonal escape. Recent developments in T cell and natural killer cell homeostasis and reconstitution are reviewed, with implications for prevention and treatment of relapse, as is the application of modern genome sequencing to defining the biologic basis of GVM, clonal escape, and relapse after HSCT.

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - National Cancer Institute (U.S.)

KW - Neoplasm Recurrence, Local

KW - Neoplasms

KW - Transplantation Conditioning

KW - Transplantation, Autologous

KW - United States

U2 - 10.1016/j.bbmt.2013.08.010

DO - 10.1016/j.bbmt.2013.08.010

M3 - SCORING: Journal article

C2 - 24018395

VL - 19

SP - 1537

EP - 1545

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 11

ER -